What side effects are associated with this type of intervention?

The most common treatments for depression include SSRIs, SNRIs, and tricyclic antidepressants (TCAs). SSRIs, such as fluoxetine and sertraline, often cause side effects like nausea, insomnia, sexual dysfunction, and weight gain. SNRIs, such as duloxetine and venlafaxine, can lead to similar side effects, including increased blood pressure. TCAs, such as amitriptyline, are associated with sedation, weight gain, dry mouth, and constipation. It is important to discuss these potential side effects with a healthcare provider to determine the most appropriate treatment.

What prior FDA approvals exist?

The FDA has approved several antidepressants for the treatment of depression, including SSRIs like fluoxetine and paroxetine, and SNRIs like venlafaxine and duloxetine. These medications have been shown to be effective in numerous clinical trials. Additionally, combining these pharmacotherapies with cognitive behavioral therapy (CBT) has been found to improve outcomes, particularly in treatment-resistant cases. This approach aligns with the clinical decision-making algorithms being studied, which involve triaging and adapting levels of care based on symptom severity and treatment response.

What other types of research exist?

Promising novel alternatives to clinical decision-making algorithms for depression treatment in 2024 include: 1) Digital Therapeutics: These involve the use of software-based interventions, such as mobile apps and online platforms, to deliver cognitive behavioral therapy (CBT) and other evidence-based treatments. 2) Personalized Medicine: This approach tailors treatment plans based on genetic, biomarker, and phenotypic data to optimize therapeutic outcomes. 3) Artificial Intelligence (AI) and Machine Learning: AI can analyze large datasets to predict treatment responses and recommend personalized treatment plans. 4) Telepsychiatry: Remote psychiatric services can increase access to care, especially in underserved areas, and provide continuous monitoring and support. 5) Integrative Approaches: Combining pharmacotherapy with lifestyle interventions, such as exercise, diet, and mindfulness, to address multiple aspects of depression.

← Back to Search

Behavioral Intervention

Psychological Care Strategies for Depression and Anxiety

N/A

Recruiting

Led By Kate Taylor, Ph.D

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline

Awards & highlights

No Placebo-Only Group

Summary

This trial tests different methods to decide and adjust mental health care for community college students at ELAC. It aims to find the best way to help students with their mental health by using regular check-ins to guide their care.

Who is the study for?

This trial is for students aged 18-40 at East Los Angeles College, either uninsured or on California Medicaid, with internet access. It's not for those needing specialized care for severe disorders, currently under psychiatric treatment unwilling to transfer to STAND, or unable to understand the study requirements.

What is being tested?

The S.T.A.N.D. project tests decision-making algorithms in triaging and adapting mental health care levels among diverse low-income college students. They'll be randomly assigned to symptom severity or data-driven groups and receive varying online prevention and therapy services.

What are the potential side effects?

Since this trial involves psychological interventions like cognitive behavioral therapy rather than medication, side effects may include emotional discomfort due to discussing personal issues but are generally considered minimal compared to drug treatments.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 40 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 40 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 40 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Baseline academic functioning

Baseline social, occupational, and home functioning

Baseline symptom severity for mental health

+5 more

Secondary study objectives

Abstract reasoning

Acculturative Stress

Beliefs about mental health treatment and stigma

+27 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Data-Driven Decision-MakingExperimental Treatment3 Interventions

Using data-driven algorithm that considers social determinants of mental health, early life adversity/stress, predisposing, enabling and need influences upon health services use, and comprehensive mental health status to guide triaging and adapting level of care.

Group II: Symptom Severity Decision-MakingActive Control3 Interventions

Using current symptom severity level to guide triaging and adapting level of care.

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for depression include pharmacotherapy and psychotherapy. Pharmacotherapy often involves the use of antidepressants such as SSRIs, SNRIs, and tricyclic antidepressants, which increase levels of neurotransmitters like serotonin and norepinephrine in the brain to improve mood and emotional stability. Psychotherapy, including cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT), focuses on changing negative thought patterns and enhancing emotional regulation. Understanding these mechanisms is important for depression patients as it helps in customizing treatment plans to individual needs, thereby improving treatment outcomes and reducing the likelihood of relapse.

Studying treatment-effect heterogeneity in precision medicine through induced subgroups.Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.